Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

SFRP1 reduction results in an increased sensitivity to TGF-β signaling

Authors: Kelly J Gauger, Kerry L Chenausky, Molly E Murray, Sallie S Schneider

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Transforming growth factor (TGF)-β plays a dual role during mammary gland development and tumorigenesis and has been shown to stimulate epithelial-mesenchymal transition (EMT) as well as cellular migration. The Wnt/β-catenin pathway is also implicated in EMT and inappropriate activation of the Wnt/β-catenin signaling pathway leads to the development of several human cancers, including breast cancer. Secreted frizzled-related protein 1 (SFRP1) antagonizes this pathway and loss of SFRP1 expression is frequently observed in breast tumors and breast cancer cell lines. We previously showed that when SFRP1 is knocked down in immortalized non-malignant mammary epithelial cells, the cells (TERT-siSFRP1) acquire characteristics associated with breast tumor initiating cells. The phenotypic and genotypic changes that occur in response to SFRP1 loss are consistent with EMT, including a substantial increase in the expression of ZEB2. Considering that ZEB2 has been shown to interact with mediators of TGF-β signaling, we sought to determine whether TGF-β signaling is altered in TERT-siSFRP1 cells.

Methods

Luciferase reporter assays and real-time PCR analysis were employed to measure TGF-β transcriptional targets. Western blot analysis was used to evaluate TGF-β-mediated ERK1/2 phosphorylation. Migration chamber assays were utilized to quantify cellular migration. TERT-siSFRP1 cells were transfected with Stealth RNAi™ siRNA in order to knock-down the expression of ZEB2.

Results

TERT-siSFRP1 cells exhibit a significant increase in both TGF-β-mediated luciferase activity as well as TGF-β transcriptional targets, including Integrin β3 and PAI-1. Phosphorylation of ERK1/2 is increased in TERT-siSFRP1 cells in response to enhanced TGF-β signaling. Furthermore, when the TGF-β pathway is blocked with a TGF-βR antagonist (LY364947), cellular migration is significantly hindered. Finally, we found that when ZEB2 is knocked-down, there is a significant reduction in the expression of exogeneous and endogenous TGF-β transcriptional targets and cellular migration is impeded.

Conclusions

We demonstrate that down-regulation of SFRP1 renders mammary epithelial cells more sensitive to TGF-β signaling which can be partially ameliorated by blocking the expression of ZEB2.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
2.
go back to reference Roberts AB, Wakefield LM: The two faces of transforming growth factor beta in carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2003, 100: 8621-8623. 10.1073/pnas.1633291100.CrossRefPubMedPubMedCentral Roberts AB, Wakefield LM: The two faces of transforming growth factor beta in carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2003, 100: 8621-8623. 10.1073/pnas.1633291100.CrossRefPubMedPubMedCentral
3.
go back to reference Reynisdottir I, Polyak K, Iavarone A, Massague J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes & development. 1995, 9: 1831-1845.CrossRef Reynisdottir I, Polyak K, Iavarone A, Massague J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes & development. 1995, 9: 1831-1845.CrossRef
4.
go back to reference Savagner P: Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays. 2001, 23: 912-923. 10.1002/bies.1132.CrossRefPubMed Savagner P: Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays. 2001, 23: 912-923. 10.1002/bies.1132.CrossRefPubMed
5.
go back to reference Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, et al: Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. The Journal of clinical investigation. 2002, 109: 1551-1559.CrossRefPubMedPubMedCentral Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, et al: Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. The Journal of clinical investigation. 2002, 109: 1551-1559.CrossRefPubMedPubMedCentral
6.
go back to reference Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL: Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene. 2006, 25: 3408-3423. 10.1038/sj.onc.1208964.CrossRefPubMed Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL: Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene. 2006, 25: 3408-3423. 10.1038/sj.onc.1208964.CrossRefPubMed
7.
go back to reference Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J: Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proceedings of the National Academy of Sciences of the United States of America. 2003, 100: 8430-8435. 10.1073/pnas.0932636100.CrossRefPubMedPubMedCentral Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J: Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proceedings of the National Academy of Sciences of the United States of America. 2003, 100: 8430-8435. 10.1073/pnas.0932636100.CrossRefPubMedPubMedCentral
8.
go back to reference Polakis P: Wnt signaling and cancer. Genes & development. 2000, 14: 1837-1851. Polakis P: Wnt signaling and cancer. Genes & development. 2000, 14: 1837-1851.
10.
go back to reference Brennan KR, Brown AM: Wnt proteins in mammary development and cancer. Journal of mammary gland biology and neoplasia. 2004, 9: 119-131. 10.1023/B:JOMG.0000037157.94207.33.CrossRefPubMed Brennan KR, Brown AM: Wnt proteins in mammary development and cancer. Journal of mammary gland biology and neoplasia. 2004, 9: 119-131. 10.1023/B:JOMG.0000037157.94207.33.CrossRefPubMed
11.
go back to reference Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC, Rudikoff S, Aaronson SA, Varmus HE, Rubin JS: Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proceedings of the National Academy of Sciences of the United States of America. 1997, 94: 6770-6775. 10.1073/pnas.94.13.6770.CrossRefPubMedPubMedCentral Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC, Rudikoff S, Aaronson SA, Varmus HE, Rubin JS: Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proceedings of the National Academy of Sciences of the United States of America. 1997, 94: 6770-6775. 10.1073/pnas.94.13.6770.CrossRefPubMedPubMedCentral
12.
go back to reference Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA: Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. The Journal of biological chemistry. 1999, 274: 16180-16187. 10.1074/jbc.274.23.16180.CrossRefPubMed Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA: Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. The Journal of biological chemistry. 1999, 274: 16180-16187. 10.1074/jbc.274.23.16180.CrossRefPubMed
13.
go back to reference Zhou Z, Wang J, Han X, Zhou J, Linder S: Up-regulation of human secreted frizzled homolog in apoptosis and its down-regulation in breast tumors. International journal of cancer. 1998, 78: 95-99. 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4.CrossRefPubMed Zhou Z, Wang J, Han X, Zhou J, Linder S: Up-regulation of human secreted frizzled homolog in apoptosis and its down-regulation in breast tumors. International journal of cancer. 1998, 78: 95-99. 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4.CrossRefPubMed
14.
go back to reference Wong SC, Lo SF, Lee KC, Yam JW, Chan JK, Wendy Hsiao WL: Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol. 2002, 196: 145-153. 10.1002/path.1035.CrossRefPubMed Wong SC, Lo SF, Lee KC, Yam JW, Chan JK, Wendy Hsiao WL: Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol. 2002, 196: 145-153. 10.1002/path.1035.CrossRefPubMed
15.
go back to reference Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, Stohr R, Simon R, Sauter G, Leibiger H, et al: Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. International journal of oncology. 2004, 25: 641-649.PubMed Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, Stohr R, Simon R, Sauter G, Leibiger H, et al: Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. International journal of oncology. 2004, 25: 641-649.PubMed
16.
go back to reference Gauger KJ, Hugh JM, Troester MA, Schneider SS: Down-regulation of sfrp1 in a mammary epithelial cell line promotes the development of a cd44high/cd24low population which is invasive and resistant to anoikis. Cancer cell international. 2009, 9: 11-10.1186/1475-2867-9-11.CrossRefPubMedPubMedCentral Gauger KJ, Hugh JM, Troester MA, Schneider SS: Down-regulation of sfrp1 in a mammary epithelial cell line promotes the development of a cd44high/cd24low population which is invasive and resistant to anoikis. Cancer cell international. 2009, 9: 11-10.1186/1475-2867-9-11.CrossRefPubMedPubMedCentral
17.
go back to reference Verschueren K, Remacle JE, Collart C, Kraft H, Baker BS, Tylzanowski P, Nelles L, Wuytens G, Su MT, Bodmer R, et al: SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5'-CACCT sequences in candidate target genes. The Journal of biological chemistry. 1999, 274: 20489-20498. 10.1074/jbc.274.29.20489.CrossRefPubMed Verschueren K, Remacle JE, Collart C, Kraft H, Baker BS, Tylzanowski P, Nelles L, Wuytens G, Su MT, Bodmer R, et al: SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5'-CACCT sequences in candidate target genes. The Journal of biological chemistry. 1999, 274: 20489-20498. 10.1074/jbc.274.29.20489.CrossRefPubMed
18.
go back to reference Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, Tulchinsky E, Van Roy F, Berx G: SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic acids research. 2005, 33: 6566-6578. 10.1093/nar/gki965.CrossRefPubMedPubMedCentral Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, Tulchinsky E, Van Roy F, Berx G: SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic acids research. 2005, 33: 6566-6578. 10.1093/nar/gki965.CrossRefPubMedPubMedCentral
19.
go back to reference Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162: 156-159. 10.1016/0003-2697(87)90021-2.CrossRefPubMed Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162: 156-159. 10.1016/0003-2697(87)90021-2.CrossRefPubMed
20.
go back to reference Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Baron AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, et al: The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. The Journal of clinical investigation. 2009, 119: 2678-2690. 10.1172/JCI37815.CrossRefPubMedPubMedCentral Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Baron AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, et al: The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. The Journal of clinical investigation. 2009, 119: 2678-2690. 10.1172/JCI37815.CrossRefPubMedPubMedCentral
21.
go back to reference Miyazono K: Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proceedings of the Japan Academy. 2009, 85: 314-323. 10.2183/pjab.85.314.CrossRefPubMedPubMedCentral Miyazono K: Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proceedings of the Japan Academy. 2009, 85: 314-323. 10.2183/pjab.85.314.CrossRefPubMedPubMedCentral
22.
go back to reference Sandler MA, Zhang JN, Westerhausen DR, Billadello JJ: A novel protein interacts with the major transforming growth factor-beta responsive element in the plasminogen activator inhibitor type-1 gene. The Journal of biological chemistry. 1994, 269: 21500-21504.PubMed Sandler MA, Zhang JN, Westerhausen DR, Billadello JJ: A novel protein interacts with the major transforming growth factor-beta responsive element in the plasminogen activator inhibitor type-1 gene. The Journal of biological chemistry. 1994, 269: 21500-21504.PubMed
23.
go back to reference Ignotz RA, Heino J, Massague J: Regulation of cell adhesion receptors by transforming growth factor-beta. Regulation of vitronectin receptor and LFA-1. The Journal of biological chemistry. 1989, 264: 389-392.PubMed Ignotz RA, Heino J, Massague J: Regulation of cell adhesion receptors by transforming growth factor-beta. Regulation of vitronectin receptor and LFA-1. The Journal of biological chemistry. 1989, 264: 389-392.PubMed
24.
go back to reference Giehl K, Imamichi Y, Menke A: Smad4-independent TGF-beta signaling in tumor cell migration. Cells, tissues, organs. 2007, 185: 123-130. 10.1159/000101313.CrossRefPubMed Giehl K, Imamichi Y, Menke A: Smad4-independent TGF-beta signaling in tumor cell migration. Cells, tissues, organs. 2007, 185: 123-130. 10.1159/000101313.CrossRefPubMed
25.
go back to reference Attisano L, Labbe E: TGFbeta and Wnt pathway cross-talk. Cancer metastasis reviews. 2004, 23: 53-61. 10.1023/A:1025811012690.CrossRefPubMed Attisano L, Labbe E: TGFbeta and Wnt pathway cross-talk. Cancer metastasis reviews. 2004, 23: 53-61. 10.1023/A:1025811012690.CrossRefPubMed
27.
go back to reference Labbe E, Lock L, Letamendia A, Gorska AE, Gryfe R, Gallinger S, Moses HL, Attisano L: Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer research. 2007, 67: 75-84. 10.1158/0008-5472.CAN-06-2559.CrossRefPubMed Labbe E, Lock L, Letamendia A, Gorska AE, Gryfe R, Gallinger S, Moses HL, Attisano L: Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer research. 2007, 67: 75-84. 10.1158/0008-5472.CAN-06-2559.CrossRefPubMed
28.
go back to reference Hussein SM, Duff EK, Sirard C: Smad4 and beta-catenin co-activators functionally interact with lymphoid-enhancing factor to regulate graded expression of Msx2. The Journal of biological chemistry. 2003, 278: 48805-48814. 10.1074/jbc.M305472200.CrossRefPubMed Hussein SM, Duff EK, Sirard C: Smad4 and beta-catenin co-activators functionally interact with lymphoid-enhancing factor to regulate graded expression of Msx2. The Journal of biological chemistry. 2003, 278: 48805-48814. 10.1074/jbc.M305472200.CrossRefPubMed
29.
go back to reference James D, Levine AJ, Besser D, Hemmati-Brivanlou A: TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development (Cambridge, England). 2005, 132: 1273-1282.CrossRef James D, Levine AJ, Besser D, Hemmati-Brivanlou A: TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development (Cambridge, England). 2005, 132: 1273-1282.CrossRef
30.
go back to reference Gauger KJ, Rodriguez-Cortes A, Hartwich M, Schneider SS: Rhodiola Crenulata inhibits the tumorigenic properties of invasive mammary epithelial cells with stem cell characteristics. Journal of Medicinal Plants Research. 2010, 5: Gauger KJ, Rodriguez-Cortes A, Hartwich M, Schneider SS: Rhodiola Crenulata inhibits the tumorigenic properties of invasive mammary epithelial cells with stem cell characteristics. Journal of Medicinal Plants Research. 2010, 5:
31.
go back to reference Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, et al: Molecular definition of breast tumor heterogeneity. Cancer cell. 2007, 11: 259-273. 10.1016/j.ccr.2007.01.013.CrossRefPubMed Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, et al: Molecular definition of breast tumor heterogeneity. Cancer cell. 2007, 11: 259-273. 10.1016/j.ccr.2007.01.013.CrossRefPubMed
32.
go back to reference Baum O, Hlushchuk R, Forster A, Greiner R, Clezardin P, Zhao Y, Djonov V, Gruber G: Increased invasive potential and up-regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the beta3 integrin subunit. International journal of oncology. 2007, 30: 325-332.PubMed Baum O, Hlushchuk R, Forster A, Greiner R, Clezardin P, Zhao Y, Djonov V, Gruber G: Increased invasive potential and up-regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the beta3 integrin subunit. International journal of oncology. 2007, 30: 325-332.PubMed
33.
go back to reference Galliher AJ, Schiemann WP: Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer research. 2007, 67: 3752-3758. 10.1158/0008-5472.CAN-06-3851.CrossRefPubMed Galliher AJ, Schiemann WP: Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer research. 2007, 67: 3752-3758. 10.1158/0008-5472.CAN-06-3851.CrossRefPubMed
34.
go back to reference Sheldrake HM, Patterson LH: Function and antagonism of beta3 integrins in the development of cancer therapy. Current cancer drug targets. 2009, 9: 519-540. 10.2174/156800909788486713.CrossRefPubMed Sheldrake HM, Patterson LH: Function and antagonism of beta3 integrins in the development of cancer therapy. Current cancer drug targets. 2009, 9: 519-540. 10.2174/156800909788486713.CrossRefPubMed
35.
go back to reference Ulisse S, Baldini E, Sorrenti S, D'Armiento M: The urokinase plasminogen activator system: a target for anti-cancer therapy. Current cancer drug targets. 2009, 9: 32-71. 10.2174/156800909787314002.CrossRefPubMed Ulisse S, Baldini E, Sorrenti S, D'Armiento M: The urokinase plasminogen activator system: a target for anti-cancer therapy. Current cancer drug targets. 2009, 9: 32-71. 10.2174/156800909787314002.CrossRefPubMed
36.
go back to reference Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH: Evolving role of uPA/uPAR system in human cancers. Cancer treatment reviews. 2008, 34: 122-136. 10.1016/j.ctrv.2007.10.005.CrossRefPubMed Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH: Evolving role of uPA/uPAR system in human cancers. Cancer treatment reviews. 2008, 34: 122-136. 10.1016/j.ctrv.2007.10.005.CrossRefPubMed
37.
go back to reference Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature medicine. 1998, 4: 923-928. 10.1038/nm0898-923.CrossRefPubMed Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature medicine. 1998, 4: 923-928. 10.1038/nm0898-923.CrossRefPubMed
38.
go back to reference Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ: Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer research. 2000, 60: 5839-5847.PubMed Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ: Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer research. 2000, 60: 5839-5847.PubMed
39.
go back to reference Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA: Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost. 2006, 4: 2710-2715. 10.1111/j.1538-7836.2006.02244.x.CrossRefPubMed Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA: Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost. 2006, 4: 2710-2715. 10.1111/j.1538-7836.2006.02244.x.CrossRefPubMed
40.
go back to reference Maillard C, Jost M, Romer MU, Brunner N, Houard X, Lejeune A, Munaut C, Bajou K, Melen L, Dano K, et al: Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. Neoplasia (New York, NY. 2005, 7: 57-66.CrossRef Maillard C, Jost M, Romer MU, Brunner N, Houard X, Lejeune A, Munaut C, Bajou K, Melen L, Dano K, et al: Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. Neoplasia (New York, NY. 2005, 7: 57-66.CrossRef
41.
go back to reference Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I, Reich R, Davidson B: Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer. 2005, 103: 1631-1643. 10.1002/cncr.20946.CrossRefPubMed Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I, Reich R, Davidson B: Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer. 2005, 103: 1631-1643. 10.1002/cncr.20946.CrossRefPubMed
42.
go back to reference Imamichi Y, Waidmann O, Hein R, Eleftheriou P, Giehl K, Menke A: TGF beta-induced focal complex formation in epithelial cells is mediated by activated ERK and JNK MAP kinases and is independent of Smad4. Biol Chem. 2005, 386: 225-236. 10.1515/BC.2005.028.CrossRefPubMed Imamichi Y, Waidmann O, Hein R, Eleftheriou P, Giehl K, Menke A: TGF beta-induced focal complex formation in epithelial cells is mediated by activated ERK and JNK MAP kinases and is independent of Smad4. Biol Chem. 2005, 386: 225-236. 10.1515/BC.2005.028.CrossRefPubMed
43.
go back to reference Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E, Berns A: High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet. 2002, 32: 153-159. 10.1038/ng950.CrossRefPubMed Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E, Berns A: High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet. 2002, 32: 153-159. 10.1038/ng950.CrossRefPubMed
44.
go back to reference Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Molecular cell. 2001, 7: 1267-1278. 10.1016/S1097-2765(01)00260-X.CrossRefPubMed Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Molecular cell. 2001, 7: 1267-1278. 10.1016/S1097-2765(01)00260-X.CrossRefPubMed
45.
go back to reference Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, Noel A, van Roy F, Berx G, Foidart JM, Gilles C: Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene. 2006, 25: 4975-4985. 10.1038/sj.onc.1209511.CrossRefPubMed Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, Noel A, van Roy F, Berx G, Foidart JM, Gilles C: Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene. 2006, 25: 4975-4985. 10.1038/sj.onc.1209511.CrossRefPubMed
46.
go back to reference Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM: Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer research. 2003, 63: 2658-2664.PubMed Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM: Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer research. 2003, 63: 2658-2664.PubMed
Metadata
Title
SFRP1 reduction results in an increased sensitivity to TGF-β signaling
Authors
Kelly J Gauger
Kerry L Chenausky
Molly E Murray
Sallie S Schneider
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-59

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine